HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marco Wachtel Selected Research

Alveolar Rhabdomyosarcoma

1/2021Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
1/2020Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
1/2020Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma.
1/2018PAX3-FOXO1: Zooming in on an "undruggable" target.
1/2017PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
11/2016The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.
11/2016Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
8/2015Unpeaceful roles of mutant PAX proteins in cancer.
1/2015PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.
5/2008Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marco Wachtel Research Topics

Disease

25Neoplasms (Cancer)
09/2022 - 02/2006
11Alveolar Rhabdomyosarcoma
01/2021 - 08/2004
10Rhabdomyosarcoma
01/2021 - 08/2004
6Sarcoma (Soft Tissue Sarcoma)
01/2022 - 06/2010
5Genetic Translocation (Chromosomal Translocation)
01/2022 - 07/2009
4Ewing Sarcoma (Sarcoma, Ewing)
09/2022 - 11/2012
3Carcinogenesis
01/2020 - 08/2015
2Embryonal Rhabdomyosarcoma
01/2021 - 08/2004
2Leukemia
01/2018 - 08/2015
1Thyroid Neoplasms (Thyroid Cancer)
08/2015
1Glioma (Gliomas)
07/2009
1Breast Neoplasms (Breast Cancer)
07/2009
1Melanoma (Melanoma, Malignant)
07/2009
1Lymphoma (Lymphomas)
06/2009

Drug/Important Bio-Agent (IBA)

11Proteins (Proteins, Gene)FDA Link
09/2022 - 08/2004
7Transcription Factors (Transcription Factor)IBA
01/2022 - 05/2008
5Pharmaceutical PreparationsIBA
01/2022 - 07/2009
4ChromatinIBA
11/2021 - 01/2017
3EWS-FLI fusion proteinIBA
09/2022 - 01/2022
3Oncogene Proteins (Oncogene Protein)IBA
01/2022 - 01/2021
2FenretinideIBA
01/2021 - 01/2020
2PAX3 Transcription FactorIBA
01/2015 - 05/2008
2Cadherins (E-Cadherin)IBA
06/2009 - 02/2006
1fimepinostatIBA
01/2022
1AntibodiesIBA
01/2021
1Monoclonal AntibodiesIBA
01/2021
1RNA (Ribonucleic Acid)IBA
05/2020
1Aurora Kinase AIBA
01/2020
1navitoclaxIBA
01/2020
1Dynamins (Dynamin)IBA
01/2020
1Mi-2 Nucleosome Remodeling and Deacetylase ComplexIBA
01/2020
1FurinIBA
11/2016
1Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA
11/2016
1BI 2536IBA
01/2015
1Biological ProductsIBA
10/2014
1midostaurinIBA
11/2012
1Histone Deacetylases (Histone Deacetylase)IBA
06/2010
1Phosphotransferases (Kinase)IBA
06/2010
1Proteasome Endopeptidase Complex (Proteasome)IBA
06/2010
1tyrosine receptor (receptor, tyrosine)IBA
06/2010
1Cannabinoid Receptor AgonistsIBA
07/2009
1Dronabinol (THC)FDA LinkGeneric
07/2009
1HU 211 (HU 210)IBA
07/2009
1Cannabinoid Receptors (Cannabinoid Receptor)IBA
07/2009
1Fibrillin-2IBA
06/2009
1Biomarkers (Surrogate Marker)IBA
06/2009
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
08/2004
1OligonucleotidesIBA
08/2004
1Pyridinolcarbamate (P23)IBA
08/2004

Therapy/Procedure

9Therapeutics
01/2021 - 05/2008
2Radiotherapy
01/2021 - 01/2021
2Drug Therapy (Chemotherapy)
01/2021 - 01/2021